Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
RA CAPITAL MANAGEMENT L.P. | 5,551,295 18.700% |
1,777,778 (+47.11%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Chimerix, Inc. CMRX |
RA CAPITAL MANAGEMENT L.P. | 8,800,000 9.900% |
2,298,376 (+35.35%) |
Filing History |
| 2024-02-14 5:01 pm Sale |
2023-12-31 | 13G | CureVac N.V. CVAC |
RA CAPITAL MANAGEMENT L.P. | 2,744,270 1.200% |
-9,501,685 (-77.59%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | ImmunoGen, Inc. IMGN |
RA CAPITAL MANAGEMENT L.P. | 26,916,027 9.990% |
4,840,869 (+21.93%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN |
RA CAPITAL MANAGEMENT L.P. | 5,903,234 9.990% |
1,505,866 (+34.24%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Ascendis Pharma A/S ASND |
RA CAPITAL MANAGEMENT L.P. | 10,107,400 17.500% |
140,228 (+1.41%) |
Filing History |
| 2024-02-14 5:01 pm Sale |
2023-12-31 | 13G | Avidity Biosciences, Inc. RNA |
RA CAPITAL MANAGEMENT L.P. | 2,454,533 3.300% |
-3,000,000 (-55.00%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
RA CAPITAL MANAGEMENT L.P. | 7,809,852 9.000% |
769,230 (+10.93%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA CAPITAL MANAGEMENT L.P. | 11,609,704 18.800% |
1,923,076 (+19.85%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Geron Corporation GERN |
RA CAPITAL MANAGEMENT L.P. | 55,145,502 9.990% |
6,722,291 (+13.88%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | GH Research PLC GHRS |
RA CAPITAL MANAGEMENT L.P. | 5,587,333 10.700% |
26,215 (+0.47%) |
Filing History |
| 2024-02-14 5:01 pm Sale |
2023-12-31 | 13G | Gracell Biotechnologies Inc. GRCL |
RA CAPITAL MANAGEMENT L.P. | 48,600,221 9.990% |
-79 (-0.00%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA CAPITAL MANAGEMENT L.P. | 4,724,352 9.990% |
870,485 (+22.59%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | MacroGenics, Inc. MGNX |
RA CAPITAL MANAGEMENT L.P. | 4,053,077 6.500% |
288,206 (+7.66%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | RxSight, Inc. RXST |
RA CAPITAL MANAGEMENT L.P. | 3,404,285 9.500% |
351,489 (+11.51%) |
Filing History |
| 2024-02-14 5:01 pm Sale |
2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
RA CAPITAL MANAGEMENT L.P. | 18,670,089 9.990% |
-20,779 (-0.11%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Tenaya Therapeutics, Inc. TNYA |
RA CAPITAL MANAGEMENT L.P. | 6,948,236 9.990% |
519,753 (+8.09%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Vaxcyte, Inc. PCVX |
RA CAPITAL MANAGEMENT L.P. | 9,685,079 9.990% |
1,531,520 (+18.78%) |
Filing History |
| 2024-02-14 5:01 pm Sale |
2023-12-31 | 13G | Verona Pharma plc VRNA |
RA CAPITAL MANAGEMENT L.P. | 7,503,976 9.990% |
-188,014 (-2.44%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Harpoon Therapeutics, Inc. HARP |
RA CAPITAL MANAGEMENT L.P. | 1,712,792 9.990% |
11,222 (+0.66%) |
Filing History |